Anti-angiogenic Therapies in Cancer: Mechanistic Insights
노바스템
2024-04-18
조회수 251
The review by El-Kenawi and El-Remessy outlines the critical role of angiogenesis in tumor growth and metastasis, highlighting the therapeutic potential of targeting angiogenic processes in cancer treatment. Angiogenesis, the formation of new blood vessels, is essential for tumor progression by supplying necessary nutrients and oxygen. The paper classifies angiogenesis inhibitors into direct and indirect types. Direct inhibitors target the endothelial cells forming new blood vessels, while indirect inhibitors act by inhibiting angiogenic signals from tumor or surrounding stromal cells, including various growth factors and cytokines. The review elaborates on different mechanisms through which these inhibitors work, such as interfering with the vascular endothelial growth factor (VEGF) pathway, which is pivotal in mediating angiogenesis. The authors discuss the use of these inhibitors both as standalone therapies and in combination with other cancer treatments, emphasizing the enhanced efficacy of combination therapies in clinical studies.
The mechanisms targeted by anti-angiogenic therapies in cancer could be analogous to strategies in regenerative medicine and stem cell therapy, such as those employed by Novastem. For instance, regulating angiogenesis could enhance the efficacy of stem cell therapies in tissue regeneration and repair, similar to how it restricts tumor growth. Understanding these pathways might help improve the delivery and integration of stem cell-derived therapies in pathological conditions where angiogenesis is a factor.
Dual Nature of Angiogenesis Inhibition: Direct inhibitors affect the endothelial cells directly, while indirect inhibitors modulate the tumor microenvironment or block growth factor activities.
Enhanced Effects with Combination Therapy: The synergy between anti-angiogenic agents and traditional cancer therapies can lead to improved patient outcomes, highlighting the potential for integrating such strategies in stem cell therapies.
Future Directions: Ongoing research into the detailed mechanisms of angiogenesis and resistance to current therapies could pave the way for next-generation anti-angiogenic agents and possibly influence approaches in stem cell therapy.
The review by El-Kenawi and El-Remessy outlines the critical role of angiogenesis in tumor growth and metastasis, highlighting the therapeutic potential of targeting angiogenic processes in cancer treatment. Angiogenesis, the formation of new blood vessels, is essential for tumor progression by supplying necessary nutrients and oxygen. The paper classifies angiogenesis inhibitors into direct and indirect types. Direct inhibitors target the endothelial cells forming new blood vessels, while indirect inhibitors act by inhibiting angiogenic signals from tumor or surrounding stromal cells, including various growth factors and cytokines. The review elaborates on different mechanisms through which these inhibitors work, such as interfering with the vascular endothelial growth factor (VEGF) pathway, which is pivotal in mediating angiogenesis. The authors discuss the use of these inhibitors both as standalone therapies and in combination with other cancer treatments, emphasizing the enhanced efficacy of combination therapies in clinical studies.
The mechanisms targeted by anti-angiogenic therapies in cancer could be analogous to strategies in regenerative medicine and stem cell therapy, such as those employed by Novastem. For instance, regulating angiogenesis could enhance the efficacy of stem cell therapies in tissue regeneration and repair, similar to how it restricts tumor growth. Understanding these pathways might help improve the delivery and integration of stem cell-derived therapies in pathological conditions where angiogenesis is a factor.
#Angiogenesis #CancerTherapy #VEGF #DirectInhibitors #IndirectInhibitors #StemCellTherapy #RegenerativeMedicine #Novastem